Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy

Abstract Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstrated able to improve the clinical picture of MMN patients, ameliorating motor symptoms and/o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luca Gentile, Massimo Russo, Carmelo Rodolico, Ilenia Arimatea, Giuseppe Vita, Antonio Toscano, Anna Mazzeo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/949207f73311409782fe52dc677986fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:949207f73311409782fe52dc677986fd
record_format	dspace
spelling	oai:doaj.org-article:949207f73311409782fe52dc677986fd2021-12-02T13:41:10ZLong-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy10.1038/s41598-021-88711-92045-2322https://doaj.org/article/949207f73311409782fe52dc677986fd2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88711-9https://doaj.org/toc/2045-2322Abstract Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstrated able to improve the clinical picture of MMN patients, ameliorating motor symptoms and/or preventing disease progression. Treatment with subcutaneous immunoglobulin (SCIg) has been shown to be as effective as IVIG. However, previously published data showed that follow-up of MMN patients in treatment with SCIg lasted no more than 56 months. We report herein the results of a long-term SCIg treatment follow up (up to 96 months) in a group of 8 MMN patients (6 M; 2F), previously stabilized with IVIG therapy. Clinical follow-up included the administration of Medical Research Council (MRC) sum-score, the Overall Neuropathy Limitation Scale (ONLS) and the Life Quality Index questionnaire (LQI) at baseline and then every 6 months. Once converted to SCIg, patients’ responsiveness was quite good. Strength and motor functions remained stable or even improved during this long-term follow-up with benefits on walking capability, resistance to physical efforts and ability in hand fine movements.Luca GentileMassimo RussoCarmelo RodolicoIlenia ArimateaGiuseppe VitaAntonio ToscanoAnna MazzeoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Luca Gentile Massimo Russo Carmelo Rodolico Ilenia Arimatea Giuseppe Vita Antonio Toscano Anna Mazzeo Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
description	Abstract Multifocal motor neuropathy (MMN) is a rare disease with a prevalence of less than 1 per 100,000 people. Intravenous immunoglobulin (IVIG) therapy, performed for a long-term period, has been demonstrated able to improve the clinical picture of MMN patients, ameliorating motor symptoms and/or preventing disease progression. Treatment with subcutaneous immunoglobulin (SCIg) has been shown to be as effective as IVIG. However, previously published data showed that follow-up of MMN patients in treatment with SCIg lasted no more than 56 months. We report herein the results of a long-term SCIg treatment follow up (up to 96 months) in a group of 8 MMN patients (6 M; 2F), previously stabilized with IVIG therapy. Clinical follow-up included the administration of Medical Research Council (MRC) sum-score, the Overall Neuropathy Limitation Scale (ONLS) and the Life Quality Index questionnaire (LQI) at baseline and then every 6 months. Once converted to SCIg, patients’ responsiveness was quite good. Strength and motor functions remained stable or even improved during this long-term follow-up with benefits on walking capability, resistance to physical efforts and ability in hand fine movements.
format	article
author	Luca Gentile Massimo Russo Carmelo Rodolico Ilenia Arimatea Giuseppe Vita Antonio Toscano Anna Mazzeo
author_facet	Luca Gentile Massimo Russo Carmelo Rodolico Ilenia Arimatea Giuseppe Vita Antonio Toscano Anna Mazzeo
author_sort	Luca Gentile
title	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
title_short	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
title_full	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
title_fullStr	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
title_full_unstemmed	Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
title_sort	long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/949207f73311409782fe52dc677986fd
work_keys_str_mv	AT lucagentile longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT massimorusso longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT carmelorodolico longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT ileniaarimatea longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT giuseppevita longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT antoniotoscano longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy AT annamazzeo longtermtreatmentwithsubcutaneousimmunoglobulininmultifocalmotorneuropathy
_version_	1718392632451792896

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy

Ejemplares similares